External analyst notes, journalism, and industry commentary cited with attribution.
Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
ADAPT TAVR's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for ADAPT TAVR. Showing past 6 months and next 12 months · 7 later hidden.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| ADAPT TAVR | Anteris Technologies | Surgical Device | Phase 2[ TODO: fill in ] | [ TODO: fill in ] | [ TODO: fill in ] | [ TODO: fill in ] | [ TODO: fill in ] | 0 |
| EMPagliflozin After Aortic Valve Replacement | Rigshospitalet, Denmark | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
Phase 4 |
| — |
| — |
| — |
| — |
| — |
| Transcatheter Aortic Valve Replacement Single Center Registry in Chinese Population | Second Affiliated Hospital, School of Medicine, Zhejiang University | — | Phase 4 | — | — | — | — | — |
| Perioperative Intensive Statin Therapy for Neuroprotection in TAVR（PISTNT） | Pan Xiangbin | — | Phase 4 | — | — | — | — | — |
| Interpectoral-pectoserratus Plane Block for Minimally Invasive Aortic Valve Replacement Via Right Anterior Minithoracotomy | Algemeen Ziekenhuis Maria Middelares | — | Phase 4 | — | — | — | — | — |
| TRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System | Ruijin Hospital | — | Phase 4 | — | — | — | — | — |
| Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement | Joon Bum Kim | — | Phase 4 | — | — | — | — | — |
| CT TAVR Abdomen Study | University of Maryland, Baltimore | — | Phase 4 | — | — | — | — | — |
| Patient Quality of Recovery After TAVR With Different Sedation Regimens | David Lyubashevsky | — | Phase 4 | — | — | — | — | — |
| Echo-Guided vs Fluoroscopy-Guided Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis（ECHO-TAVR） | China National Center for Cardiovascular Diseases | — | Phase 4 | — | — | — | — | — |
| ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement | Duk-Woo Park, MD | — | Phase 4 | — | — | — | — | — |
| AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation | Oslo University Hospital | — | Phase 3 | — | — | — | — | — |
| Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR | Meshalkin Research Institute of Pathology of Circulation | — | Phase 3 | — | — | — | — | — |
| Short Versus Long Antiplatelet Therapy After TAVI | University Hospital, Caen | — | Phase 3 | — | — | — | — | — |
| Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement | Leiden University Medical Center | — | Phase 3 | — | — | — | — | — |
| A Randomised Controlled Trial to Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes Than Standard-of-care Therapy Alone. | University College, London | — | Phase 2 | — | — | — | — | — |